局部BET PROTACs用于肺部局部受限蛋白质降解
Martin Hemmerling1, Jianming Liu2, Antonio Piras3
1Medicinal Chemistry, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden martin.hemmerling@astrazeneca.com.
RSC medicinal chemistry
|July 14, 2025
概括
这项研究探讨了吸入型蛋白质溶解向奇默体 (PROTACs),重点是传递参数,并引入了新的吸入型原体和额外终端域 (BET) PROTACs,用于体外和体内表征.
科学领域:
- 药用化学 医学化学
- 药物运输 药物运输 药物运输
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白质溶解向基因组 (PROTACs) 在口服生物可用性方面进行了广泛研究,以利宾斯基和维伯规则等既定药物设计原则为指导.
- 目前的专业知识大大有利于口服PROTAC的开发,对吸入或局部施用PROTAC的知识有限.
- 影响口服PROTAC生物利用性的关键物理化学性质包括分子量,脂性 (log P,log D),结合能力,极地表面积和可旋转结合.
研究的目的:
- 识别和引入影响PROTACs吸入途径的关键参数.
- 介绍了第一批专门设计用于肺部输送的吸入式原体和额外终端域 (BET) PROTACs 的例子.
- 通过体外和体外研究来描述这些新型的吸入BET PROTACs.
主要方法:
- 对口服药物吸收相关的物理化学性质的分析 (利宾斯基规则,维伯规则,日志P,日志D,极地表面积,可旋转键).
- 设计和合成针对吸入剂的新型原蛋白和额外末端域 (BET) PROTACs.
- 在体外测试以评估化合物的活性和特性.
- 在体内研究,以评估吸入PROTACs的疗效和药理学特征.
主要成果:
- 对口服可用的PROTACs的既定指南与口服药物的bRo5化学空间一致.
- 确定了影响PROTACs吸入施用途径的关键参数.
- 成功设计和表征了第一个吸入的BET PROTACs,通过体外和体外数据证明了它们的潜力.
结论:
- 对于口服PROTAC的设计,已有大量的知识,但对吸入PROTAC的专业知识还在芽中.
- 这项工作为吸入PROTAC输送的参数提供了基础的见解.
- 吸入式BET PROTACs的开发代表了肺部药物输送应用的重大进步.
相关概念视频
Regulated Protein Degradation
2.6K
2.6K
The Proteasome
9.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.1K
Regulation of Nuclear Protein Sorting
2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Covalently Linked Protein Regulators
7.3K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
7.3K
Tail-anchoring of Proteins in the ER Membrane
3.2K
Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
3.2K


